452 related articles for article (PubMed ID: 23832525)
1. Intravenous treatment with ibandronate normalizes bone matrix mineralization and reduces cortical porosity after two years in male osteoporosis: a paired biopsy study.
Misof BM; Patsch JM; Roschger P; Muschitz C; Gamsjaeger S; Paschalis EP; Prokop E; Klaushofer K; Pietschmann P; Resch H
J Bone Miner Res; 2014 Feb; 29(2):440-9. PubMed ID: 23832525
[TBL] [Abstract][Full Text] [Related]
2. Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort.
Misof BM; Roschger P; Gabriel D; Paschalis EP; Eriksen EF; Recker RR; Gasser JA; Klaushofer K
J Bone Miner Res; 2013 Mar; 28(3):442-8. PubMed ID: 23044788
[TBL] [Abstract][Full Text] [Related]
3. Bone matrix mineralization is preserved during early perimenopausal stage in healthy women: a paired biopsy study.
Misof BM; Roschger P; Blouin S; Recker R; Klaushofer K
Osteoporos Int; 2016 May; 27(5):1795-803. PubMed ID: 26650378
[TBL] [Abstract][Full Text] [Related]
4. Increased heterogeneity of bone matrix mineralization in pediatric patients prone to fractures: a biopsy study.
Tamminen IS; Misof BM; Roschger P; Mäyränpää MK; Turunen MJ; Isaksson H; Kröger H; Mäkitie O; Klaushofer K
J Bone Miner Res; 2014; 29(5):1110-7. PubMed ID: 24166885
[TBL] [Abstract][Full Text] [Related]
5. Subtle changes in bone mineralization density distribution in most severely affected patients with chronic obstructive pulmonary disease.
Misof BM; Roschger P; Jorgetti V; Klaushofer K; Borba VZ; Boguszewski CL; Cohen A; Shane E; Zhou H; Dempster DW; Moreira CA
Bone; 2015 Oct; 79():1-7. PubMed ID: 26003953
[TBL] [Abstract][Full Text] [Related]
6. Histomorphometry and Bone Matrix Mineralization Before and After Bisphosphonate Treatment in Boys With Duchenne Muscular Dystrophy: A Paired Transiliac Biopsy Study.
Misof BM; Roschger P; McMillan HJ; Ma J; Klaushofer K; Rauch F; Ward LM
J Bone Miner Res; 2016 May; 31(5):1060-9. PubMed ID: 26615086
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of monthly ibandronate in men with low bone density.
Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
[TBL] [Abstract][Full Text] [Related]
8. Differential Effects of Teriparatide and Zoledronic Acid on Bone Mineralization Density Distribution at 6 and 24 Months in the SHOTZ Study.
Dempster DW; Roschger P; Misof BM; Zhou H; Paschalis EP; Alam J; Ruff VA; Klaushofer K; Taylor KA
J Bone Miner Res; 2016 Aug; 31(8):1527-35. PubMed ID: 26931279
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
10. PTH(1-84) Administration in Hypoparathyroidism Transiently Reduces Bone Matrix Mineralization.
Misof BM; Roschger P; Dempster DW; Zhou H; Bilezikian JP; Klaushofer K; Rubin MR
J Bone Miner Res; 2016 Jan; 31(1):180-9. PubMed ID: 26111772
[TBL] [Abstract][Full Text] [Related]
11. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.
Lewiecki EM; Keaveny TM; Kopperdahl DL; Genant HK; Engelke K; Fuerst T; Kivitz A; Davies RY; Fitzpatrick LA
J Clin Endocrinol Metab; 2009 Jan; 94(1):171-80. PubMed ID: 18840641
[TBL] [Abstract][Full Text] [Related]
12. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
[TBL] [Abstract][Full Text] [Related]
13. The effect of monthly ibandronate on bone mineral density and bone turnover markers in patients with haemophilia A and B and increased risk for fracture.
Anagnostis P; Vyzantiadis TA; Charizopoulou M; Adamidou F; Karras S; Goulis DG; Karagiannis A; Garipidou V; Vakalopoulou S
Thromb Haemost; 2013 Aug; 110(2):257-63. PubMed ID: 23740140
[TBL] [Abstract][Full Text] [Related]
14. Ibandronate and calcitriol reduces fracture risk, reverses bone loss, and normalizes bone turnover after LTX.
Wagner D; Amrein K; Dimai HP; Kniepeiss D; Tscheliessnigg KH; Kornprat P; Dobnig H; Pieber T; Fahrleitner-Pammer A
Transplantation; 2012 Feb; 93(3):331-6. PubMed ID: 22217531
[TBL] [Abstract][Full Text] [Related]
15. Alfacalcidol Increases the Therapeutic Efficacy of Ibandronate on Bone Mineral Density in Japanese Women with Primary Osteoporosis.
Nakamura Y; Suzuki T; Kamimura M; Ikegami S; Uchiyama S; Kato H
Tohoku J Exp Med; 2017 Apr; 241(4):319-326. PubMed ID: 28458336
[TBL] [Abstract][Full Text] [Related]
16. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
17. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.
Hakala M; Kröger H; Valleala H; Hienonen-Kempas T; Lehtonen-Veromaa M; Heikkinen J; Tuomiranta T; Hannonen P; Paimela L;
Scand J Rheumatol; 2012 Aug; 41(4):260-6. PubMed ID: 22803768
[TBL] [Abstract][Full Text] [Related]
18. Effects of Odanacatib on bone mineralization density distribution in thoracic spine and femora of ovariectomized adult rhesus monkeys: a quantitative backscattered electron imaging study.
Fratzl-Zelman N; Roschger P; Fisher JE; Duong LT; Klaushofer K
Calcif Tissue Int; 2013 Mar; 92(3):261-9. PubMed ID: 23179105
[TBL] [Abstract][Full Text] [Related]
19. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
20. Ibandronate increases sclerostin levels and bone strength in male patients with idiopathic osteoporosis.
Muschitz C; Kocijan R; Pahr D; Patsch JM; Amrein K; Misof BM; Kaider A; Resch H; Pietschmann P
Calcif Tissue Int; 2015 Jun; 96(6):477-89. PubMed ID: 25911186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
